Mechanism(s) of butyrate transport in Caco-2 cells: role of
monocarboxylate transporter 1
Christos
Hadjiagapiou,
Larry
Schmidt,
Pradeep K.
Dudeja,
Thomas J.
Layden, and
Krishnamurthy
Ramaswamy
Section of Digestive and Liver Diseases, Department of Medicine,
University of Illinois at Chicago and the West Side Veterans Affairs
Medical Center, Chicago, Illinois 60612
 |
ABSTRACT |
The short-chain fatty acid
butyrate was readily taken up by Caco-2 cells. Transport exhibited
saturation kinetics, was enhanced by low extracellular pH, and was
Na+ independent. Butyrate uptake was unaffected by DIDS;
however,
-cyano-4-hydroxycinnamate and the butyrate analogs
propionate and L-lactate significantly inhibited uptake.
These results suggest that butyrate transport by Caco-2 cells is
mediated by a transporter belonging to the monocarboxylate transporter
family. We identified five isoforms of this transporter, MCT1, MCT3,
MCT4, MCT5, and MCT6, in Caco-2 cells by PCR, and MCT1 was found to be
the most abundant isoform by RNase protection assay. Transient
transfection of MCT1, in the antisense orientation, resulted in
significant inhibition of butyrate uptake. The cells fully recovered
from this inhibition by 5 days after transfection. In conclusion, our data showed that the MCT1 transporter may play a major role in the
transport of butyrate into Caco-2 cells.
short-chain fatty acids; intestinal absorption; antisense cDNA
 |
INTRODUCTION |
SHORT-CHAIN FATTY ACIDS
(SCFA) are the most abundant anions in the colonic lumen of many
mammals, including humans (4, 11). They are the products
of bacterial fermentation of undigested carbohydrates and proteins that
escape absorption in the small intestine. Acetate, propionate, and
butyrate, the predominant SCFAs, are readily absorbed by colonocytes,
causing rapid cellular acidification followed by
Na+-independent pH recovery and used as the preferred
source of fuel by these cells (4, 7, 8, 11, 22, 30).
Previous experiments showed a preferential utilization of SCFA in the
order of butyrate > propionate > acetate (10).
SCFA are metabolized by colonocytes into glucose, ketone bodies, and
amino acids (28, 29). Their importance to the normal
function of human colon has been well established by their use to treat
colonic diseases like diversion colitis and ulcerative colitis
(18, 31). Butyrate is oxidized more readily to
CO2 than propionate and acetate by colonocytes, and its
oxidation is independent of the presence of other SCFA
(10). It is implicated in the regulation of growth of
colonic mucosa and in vitro cell proliferation and differentiation, involving the activation of several differentiation-specific genes (19, 23, 35). Butyrate has also been shown to reduce in vivo and in vitro growth rates in colorectal cancer cells (3, 12,
21, 32, 38).
A number of recent studies have focused on elucidation of the mechanism
of SCFA transport into colonic cells. Studies in our laboratory
indicated that SCFA are transported via a SCFA/HCO3
antiporter that is independent of the
Cl
/HCO3
exchanger and of the presence
of Na+ (16, 17). Although several studies came
to similar conclusions (20, 33, 37), others suggested
different mechanisms, such as nonionic diffusion (5, 37),
a combination of nonionic diffusion and transporter activity (6,
8, 9), or an anion-exchange process involving the AE2 exchanger
(39). It is also possible that a monocarboxylate
transporter (MCT), such as MCT1 (13), can be involved, as
recently shown (27). Therefore, our studies were carried
out to elucidate the mechanism of SCFA transport in the human intestine
by characterizing the uptake of butyrate in Caco-2 cells and by
investigating the possible role of MCT1 in butyrate transport. In the
present study, we demonstrate that the transport of butyrate in Caco-2
cells exhibits typical Michaelis-Menten kinetics and that the process
is pH dependent, Na+ independent, and DIDS insensitive.
Furthermore, inhibition of butyrate transport in Caco-2 cells with the
antisense MCT1 cDNA demonstrates the possible involvement of the MCT1
transporter in the uptake process.
 |
METHODS |
Materials.
Caco-2 cells were obtained from Dr. Gail Hecht's laboratory
(Univ. of Illinois at Chicago, Chicago, IL), and
[1-14C]butyrate (specific activity 15 mCi/mmol) was
purchased from NEN (Boston, MA). Butyrate, DIDS, and
-cyano-4-hydroxycinnamate were obtained from Sigma (St. Louis, MO),
and the Bradford reagent was obtained from Bio-Rad (Hercules, CA).
LipofectAMINE PLUS reagent, Opti-MEM medium, Superscript II RT, and
oligonucleotides were purchased from GIBCO BRL (Grand Island, NY).
Radioactivity was measured in a liquid scintillation counter made by
Packard (Downers Grove, IL).
Cell culture.
Caco-2 cells were grown routinely in T-75 cm2 plastic
flasks at 37°C in a 5% CO2-95% air environment. The
culture medium consisted of high-glucose DMEM (GIBCO BRL), 10% FBS,
100 IU/ml penicillin, and 100 µg/ml streptomycin. Cells reached
confluence after 5-7 days in culture. They were used for this
study between passages 26 and 55 and plated in
12-well plates. Cells were used for experiments 2 days after confluence
and fed with fresh incubation medium the day before an experiment was
carried out.
Transport experiments.
Cells were washed twice with 1 ml Hanks' balanced salt solution (HBSS;
in mM: 1.3 CaCl2, 5.4 KCl, 0.44 K2HPO4, 0.4 MgSO4, 0.4 Na2HPO4, 4 NaHCO3, 0.5 MgCl2, 135 choline Cl, and 10 HEPES, pH 7.5) and incubated
for 30 min at room temperature in the same buffer. To initiate the
transport experiments, 0.5 ml HBSS-PIPES (pH 6.5) containing 0.2 mM
[1-14C]butyrate was added to each well and incubated for
5 min at room temperature. The supernatant was removed, and cells were
washed twice with 1 ml ice-cold HBSS-PIPES (pH 6.5). One milliliter of ethanol was added to each well to extract radioactivity and incubated for 30 min at room temperature, and the extract was counted in a liquid
scintillation counter. Cells were dissolved in 0.1 N NaOH/PBS,
and the amount of protein in each well was assayed using the Bradford method.
Cloning of MCT.
Total RNA from Caco-2 cells was obtained using STAT-60 (Tel-Test). An
oligo(dT) primer was used to reverse transcribe 10 µg of total RNA at
42°C for 60 min using SuperScript II RT. The reaction was terminated
by heating at 70°C for 15 min, followed by the addition of RNase H
and incubation at 37°C for 25 min. Two microliters of RT reaction
were used to amplify MCT1 and fragments of MCT isoforms using PCR. The
reaction was carried out using primers designed from the published
human MCT cDNA sequences. The amplification conditions were one cycle
at 94°C for 2 min, followed by 35 cycles at 94°C for 45 s,
annealing at 68°C for 1 min, and extension at 72°C for 2 min for
MCT1 cDNA or 1 min for cDNA fragments of MCT isoforms. Final extension
was carried out at 72°C for 10 min. The primers used were GI 236 and
GI 154 for the MCT1 cDNA and GI 120 and GI122, GI 347 and GI 348, GI
350 and GI 351, GI 353 and GI 352, and GI 354 and GI 355 for MCT1,
MCT3, MCT4, MCT5, and MCT6 fragments, respectively. The resulting PCR
products were cloned into pGEM-T vector (Promega, Madison, WI) and
sequenced (Sequenase v. 2, Amersham). A list of the
oligonucleotide sequences is provided in Table
1.
Transient transfection experiments.
The pRc/CMV vector was cut with Hind III restriction
endonuclease, and the resulting 3' protruding end was made blunt with Klenow enzyme. The MCT1 cDNA was ligated into the blunt-ended pRc/CMV,
and its antisense orientation was used for transfection. Caco-2 cells
were plated at 50% confluency the day before transfection in 12-well
plates. Antisense MCT1 construct (0.8 µg) or vector alone was
complexed with 5 µl LipofectAMINE PLUS reagent in 50 µl Opti-MEM
medium and incubated for 15 min. In other tubes, 2 µl of
LipofectAMINE were diluted in 50 µl Opti-MEM medium and combined with
precomplexed DNA, mixed, and incubated for 15 min at room temperature.
The cells were washed once with Opti-MEM medium, and the
DNA-LipofectAMINE PLUS complexes were added into each well
along with 400 µl Opti-MEM medium. Incubations were carried out for
3-5 h at 37°C. Media were removed, and 1 ml DMEM/10% FBS was
added to each well. Butyrate transport experiments were done 48 h
after transfection.
Ribonuclease protection assay.
[32P]CTP-labeled antisense MCT transcript was
synthesized from cDNA template using SP6 or T7 RNA polymerase.
Radioactive probe (400,000 cpm) was hybridized with 20 µg of total
RNA, extracted from Caco-2 cells, and incubated at 42°C for 20 h. After hybridization, the samples were digested with RNase T for 45 min at 37°C and ethanol precipitated. They were resuspended in
sequencing buffer, run on a 6% polyacrylamide/urea gel, and visualized
by autoradiography, exposed on an X-ray film at
80°C for 20 h.
Statistics.
Results are expressed as means ± SE. Statistical significance was
determined using the paired t-test.
 |
RESULTS |
Time- and concentration-dependent uptake of butyrate.
The time-dependent uptake of 0.2 mM [1-14C]butyrate by
Caco-2 cells was examined. As shown in Fig.
1, increasing amounts of butyrate were
transported into the cells as the time increased up to 10 min. This
increase was found to be linear between 3 min and 10 min, and a 5-min
incubation time was used for determining the initial rates of transport
on the basis of these studies. For kinetic studies, the
concentration-dependent uptake of butyrate by Caco-2 cells was examined
by incubating them for 5 min with various concentrations of butyrate up
to 10 mM (Fig. 2). The uptake was found
to exhibit typical Michaelis-Menten kinetics with a calculated
Michaelis-Menten constant (Km) of 2.6 mM and a
maximal velocity (Vmax) of 96 nmol · 5min
1 · mg protein
1.
Since Caco-2 cells differentiate fully up to 21 days after confluence, we decided to examine the uptake of butyrate by Caco-2 cells 22 days after confluence. The results (not shown) showed a calculated Km of 1.98 mM and Vmax of
82 nmol/5 min
1 · mg protein
1. These
results are similar to those results obtained from 2 days postconfluent
Caco-2 cells.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 1.
Time-dependent uptake of butyrate. Caco-2 cells were
preincubated in Hanks' balanced salt solution (HBSS)-HEPES (pH 7.5)
for 30 min and incubated with 200 µM [1-14C]butyrate in
HBSS-PIPES (pH 6.5) at room temperature. Values are means ± SE of
3 different cultures.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 2.
Concentration-dependent uptake of butyrate. Cells were
preincubated in HBSS-HEPES (pH 7.5) for 30 min and incubated with
increasing concentrations of [1-14C]butyrate in
HBSS-PIPES (pH 6.5) for 5 min. Values are means ± SE of 3 different cultures.
|
|
Effect of Na+ and pH on butyrate uptake.
Considering that the electroneutral transport of anions may be
Na+ or H+ linked, we decided to examine whether
the uptake of butyrate was Na+ dependent. Cells were
incubated with 200 µM [1-14C]butyrate for 5 min with or
without 138 mM Na+. This inward Na+ gradient
had no effect on butyrate uptake (results not shown), and therefore the
transport of this SCFA was regarded as a Na+-independent
process. Next, the effect of extracellular pH on butyrate transport
into the cells was determined. Cells were incubated with butyrate in
HBSS-PIPES at pH 7.5, 6.5, or 5.5 for 5 min at room temperature (Table
2). When the extracellular pH was reduced from 7.5 to 6.5, a twofold increase of butyrate uptake was observed, whereas further reduction of pH to 5.5 increased the uptake by sevenfold, demonstrating an acidic pH-stimulated uptake.
Effect of inhibitors.
To determine whether butyrate uptake could be associated with an
anion-exchange mechanism, the effect of DIDS at concentrations of 0.05, 0.1, and 1 mM on butyrate uptake was determined. Cells were
preincubated with or without DIDS for 15 min and incubated with
butyrate in the presence or absence of DIDS for 5 min. As can be seen
from Table 3, DIDS had no effect on
butyrate transport. We also examined whether
-cyano-4-hydroxycinnamate, at concentrations of 0.2, 0.4, and 1 mM,
can affect the butyrate uptake by Caco-2 cells. Cells were preincubated
with or without the inhibitor for 15 min and incubated with butyrate in
the presence or absence of inhibitor for 5 min. Our results (Fig.
3) showed that
-cyano-4-hydroxycinnamate, a monocarboxylate inhibitor,
significantly inhibited the transport of butyrate into cells at all
concentrations examined (P < 0.05). The highest
inhibition (45%) was observed at 1 mM concentration.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of -cyano-4-hydroxycinnamate on butyrate uptake
by Caco-2 cells. Cells were preincubated in HBSS-HEPES (pH 7.5) for 30 min and preincubated with or without -cyano-4-hydroxycinnamate in
the same buffer for 15 min. They were incubated with 200 µM
[1-14C]butyrate in the presence or absence of inhibitor
in HBSS-PIPES (pH 6.5) for 5 min. Values are means ± SE of 3 different cultures. * P < 0.05.
|
|
Effect of butyrate analogs.
The effect of substrate analogs lactate and propionate on
butyrate uptake was determined. Lactate is a monocarboxylic acid, known to be transported into cells via the MCT, and propionate, a SCFA
structurally similar to butyrate, is found in the colonic lumen. Cells
were incubated with [1-14C]butyrate in the presence or
absence of lactate or propionate for 5 min, and its uptake was
estimated. The results (Table 4) showed
that the transport of butyrate into cells was inhibited by the presence
of either analog. In the presence of lactate, the decrease was 70 and
80% at 10 and 20 mM, respectively, whereas in the presence of
propionate the inhibition was 77 and 92% at 10 and 20 mM,
respectively.
MCT isoforms in Caco-2 cells.
These results suggested that a MCT isoform plays a role in the
transport of butyrate into Caco-2 cells. We therefore examined the
presence of MCT isoforms in these cells by using RT-PCR. Our results
showed that MCT1, MCT3, MCT4, MCT5, and MCT6 isoforms are expressed in
Caco-2 cells (Fig. 4). To determine their
relative abundance of expression, we employed the RNase protection
assay using glyceraldehyde 3-phosphate dehydrogenase as an internal standard. The results (Fig. 5) showed
MCT1 to be the most abundant MCT isoform expressed in Caco-2 cells. The
MCT1 cDNA was amplified from Caco-2 total RNA with the use of PCR.
Sequence analysis showed 100% homology between the Caco-2 MCT1 cDNA
and the reported MCT 1 sequence from the human heart.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 4.
Monocarboxylate transporter (MCT) isoforms expressed in
Caco-2 cells using the PCR method. Total RNA (10 µg) from Caco-2
cells were reverse transcribed and amplified using the PCR method and
specific primers for each MCT isoform. The conditions used were 94°C
for 2 min for 1 cycle, 94°C for 45 s, annealing at 68°C for 1 min, and extension at 72°C for 1 min for 35 cycles. Ten microliters
of the PCR reaction were run on 1% agarose gel. Numbers on
left are numbers of base pairs.
|
|

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 5.
Relative abundance of mRNA of MCT isoforms in Caco-2 cells by RNase
protection assay. MCT antisense probe (400,000 cpm) was hybridized with
10 µg total RNA from Caco-2 cells. The hybridization was carried out
at 42°C for 20 h. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal standard. Left: protected
fragments (P-); right: radioactive probes used.
|
|
Effect of antisense MCT1 transfection on butyrate transport.
Studies were carried out to insert the MCT1 cDNA into pRc/CMV vector in
the antisense orientation and to transfect Caco-2 cells with this
construct or the vector alone as control. The uptake of butyrate was
determined 48 h after transfection. Our results showed that the
antisense MCT1 inhibited butyrate uptake by ~50%, whereas the vector
alone showed no inhibition (Fig. 6). Furthermore, to determine cell recovery from the effects of antisense MCT1 inhibition, we determined butyrate uptake 3, 4, and 5 days after
transfection (Fig. 7). Compared with a
50% reduction at day 2, at 3 days after transfection the
uptake was inhibited by 27% and after 4 days by 11%, with no
significant difference in the uptake between control and antisense
MCT1. The cells fully recovered from the inhibition 5 days after
transfection.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Butyrate uptake in Caco-2 cells transfected with
antisense MCT1 construct. Cells were transfected with 0.8 µg of
antisense MCT1 construct or the vector alone (pRc/CMV) for 3 h
using the LipofectAMINE PLUS reagent. Butyrate uptake was determined 2 days after transfection. Cells were preincubated in HBSS-HEPES (pH 7.5)
and incubated with 200 µM [1-14C]butyrate in HBSS-PIPES
(pH 6.5) for 5 min. Values are means ± SE of 3 separate
cultures.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Butyrate uptake recovery in cells transfected with
antisense MCT1 construct. Cells were transfected with 0.8 µg of
antisense MCT1 in pRc/CMV vector or vector alone for 3-5 h using
the LipofectAMINE PLUS reagent. Butyrate uptake was determined 3, 4, and 5 days after transfection. Cells were preincubated in HBSS-HEPES
(pH 7.5) for 30 min and incubated with 200 µM
[1-14C]butyrate for 5 min in HBSS-PIPES (pH 6.5). Values
are means ± SE of 3 separate cultures.
|
|
 |
DISCUSSION |
The present study demonstrates that the transport of butyrate
across the brush-border membrane of Caco-2 cells involves the MCT1
transporter. In this study, we have shown that butyrate was taken up by
Caco-2 cells in a concentration- and time-dependent manner. This uptake
was pH dependent, Na+ independent, and DIDS insensitive. It
was also blocked by the monocarboxylate transport inhibitor
-cyano-4-hydroxycinnamate and the substrate analogs
L-lactate and propionate. Furthermore, we have shown that
the MCT isoforms MCT1, MCT3, MCT4, MCT5, and MCT6 (13, 25)
were expressed in Caco-2 cells, and of these isoforms MCT1 was
determined to play a role in the transport of butyrate in these cells.
Earlier studies from our laboratory showed that butyrate and propionate
were readily taken up by colonic and ileal luminal membrane vesicles
via a Na+ independent SCFA/HCO3
transporter (16, 17). Similar results were reported in
other studies using various animals (20, 33, 37). In
agreement with these reports, our data showed that butyrate was
Na+ independent but readily taken up in a saturable manner,
which is a characteristic of a carrier-mediated process. Also, the
uptake was stimulated significantly with the reduction of extracellular pH, in agreement with those results obtained from pig and human colonic
luminal membranes (16, 26). This stimulated uptake was
shown to predominantly acidify the apical site of cells, as opposed to
the basal site, which is alkaline and resistant to pH perturbations
(14). It is well known that the transport via the MCT is
H+ linked, with the exception of kidney (24,
34). In correlation with an earlier report showing that the
absorption of SCFA in the colon increased the luminal pH
(36), the uptake of SCFA via the MCT could account for the
reduction of luminal H+ concentration, leading to an
increased pH.
A recent study reported an increased transport of monocarboxylic acids,
including butyrate and propionate, in HEK-293 cells transfected with
mouse AE2 cDNA, and the transport was inhibited by DIDS
(39). In addition, high concentrations of
L-lactate and propionate were transported in human and rat
erythrocytes by the band 3 protein, a
Cl
/HCO3
exchanger (2, 15).
Our data clearly showed that the butyrate transporter activity was not
inhibited by DIDS, excluding the possibility that butyrate uptake
occurred via a Cl
/HCO3
exchanger. Also,
a recent study by Alrefai et al. (1) from our laboratory
demonstrated that AE2 was found to be localized on the human colonic
basolateral membranes, as demonstrated through Western blots of
membranes with antipeptide antibodies. This is in agreement with
previous SCFA transport studies from our laboratory and others that
used human and other intestinal membrane vesicles (16, 17, 26,
33). In addition, we have shown that the monocarboxylate
inhibitor
-cyano-4-hydroxycinnamate and the butyrate analogs
L-lactate and propionate significantly inhibited the uptake of butyrate by Caco-2 cells. Similar results were obtained by other
laboratories by using pig and human colonic luminal membranes (26) and human ileal and colonic luminal membranes and rat
distal colon (16, 17, 20, 33). Furthermore, in
Xenopus oocytes transfected with MCT1 cDNA, butyrate uptake
was inhibited by pyruvate and L-lactate (27).
To further define the butyrate transporter in Caco-2 cells, we employed
antisense technology to suppress the expression of MCT1 transporter. An
antisense MCT1 construct transiently transfected into Caco-2 cells
inhibited the butyrate uptake by ~50%, supporting the involvement of
MCT1 in butyrate transport. This rate of inhibition appeared to be due
to a binding between the antisense MCT1 mRNA and its target mRNA. The
cells were found to start recovering from this inhibition by day
3 after transfection, and by day 5 the recovery was complete.
In summary, our current results demonstrate that the MCT1 isoform plays
a major role in the transport of butyrate in Caco-2 cells. The extent
of SCFA transport via the MCT1 pathway under physiological conditions
is not known at present. Our studies also demonstrate that MCT1 is not
the only MCT isoform expressed in these cells, and more studies are
needed to evaluate the contribution of other isoforms to the transport
of butyrate.
 |
ACKNOWLEDGEMENTS |
These studies were supported by the Department of Veterans Affairs
and National Institute of Diabetes and Digestive and Kidney Diseases
Grants DK-33349 (K. Ramaswamy) and DK-54016 (P. K. Dudeja).
 |
FOOTNOTES |
Address for reprint requests and other correspondence: K. Ramaswamy, Dept. of Medicine, Univ. of Illinois at Chicago, M/C 787, Section of Digestive and Liver Diseases, 840 S. Wood St., Chicago, IL
60612 (E-mail: kramaswa{at}uic.edu).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 9 March 2000; accepted in final form 10 May 2000.
 |
REFERENCES |
1.
Alrefai, WA,
Barakat J,
Tyagi S,
Layden TJ,
Ramaswamy K,
and
Dudeja PK.
AE-2 and AE-3 anion exchanger isoforms are localized to the basolateral but not to the apical membranes in the human intestine (Abstract).
Gastroenterology
112:
A344,
1997[ISI].
2.
Aubert, L,
and
Motais R.
Molecular features of organic anion permeability in ox red blood cell.
J Physiol (Lond)
246:
159-179,
1975[Abstract].
3.
Boffa, LC,
Lupton JR,
Mariani MR,
Ceppi M,
Newmark HL,
Scalmati A,
and
Lipkin M.
Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats.
Cancer Res
52:
5906-5912,
1992[Abstract].
4.
Bugaut, M.
Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals.
Comp Biochem Physiol B Biochem Mol Biol
86:
439-472,
1987[ISI].
5.
Charney, AN,
Micic L,
and
Egnor RW.
Nonionic diffusion of short-chain fatty acids across rat colon.
Am J Physiol Gastrointest Liver Physiol
274:
G518-G524,
1998[Abstract/Free Full Text].
6.
Chu, S,
and
Montrose MH.
Extracellular pH regulation in microdomains of colonic crypts: effects of short-chain fatty acids.
Proc Natl Acad Sci USA
92:
3303-3307,
1995[Abstract].
7.
Chu, S,
and
Montrose MH.
The glow of the colonic pH microclimate kindled by short-chain fatty acids, chloride and bicarbonate.
J Physiol (Lond)
517:
315,
1999[Abstract/Free Full Text].
8.
Chu, S,
and
Montrose MH.
A Na+-independent short-chain fatty acid transporter contributes to intracellular pH regulation in murine colonocytes.
J Gen Physiol
105:
589-615,
1995[Abstract].
9.
Chu, S,
and
Montrose MH.
Non-ionic diffusion and carrier-mediated transport drive extracellular pH regulation of mouse colonic crypts.
J Physiol (Lond)
494:
783-793,
1996[Abstract].
10.
Clausen, MR,
and
Mortensen PB.
Kinetic studies on the metabolism of short-chain fatty acids and glucose by isolated rat colonocytes.
Gastroenterology
106:
423-432,
1994[ISI][Medline].
11.
Cummings, JH.
Short chain fatty acids in the human colon.
Gut
22:
763-779,
1981[ISI][Medline].
12.
DeCosse, JJ,
Miller HH,
and
Lesser ML.
Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis.
J Natl Cancer Inst
81:
1290-1297,
1989[Abstract].
13.
Garcia, CK,
Li X,
Luna J,
and
Francke U.
cDNA cloning of the human monocarboxylate transporter 1 and chromosomal localization of the SLC16A1 locus to 1p13.2-p12.
Genomics
23:
500-503,
1994[ISI][Medline].
14.
Gonda, T,
Maouyo D,
Rees SE,
and
Montrose MH.
Regulation of intracellular pH gradients by identified Na/H exchanger isoforms and a short-chain fatty acid.
Am J Physiol Gastrointest Liver Physiol
276:
G259-G270,
1999[Abstract/Free Full Text].
15.
Halestrap, AP.
Transport of pyruvate and lactate into human erythrocytes. Evidence for the involvement of the chloride carrier and a chloride-independent carrier.
Biochem J
156:
193-207,
1976[ISI][Medline].
16.
Harig, JM,
Ng EK,
Dudeja PK,
Brasitus TA,
and
Ramaswamy K.
Transport of n-butyrate into human colonic luminal membrane vesicles.
Am J Physiol Gastrointest Liver Physiol
271:
G415-G422,
1996[Abstract/Free Full Text].
17.
Harig, JM,
Soergel KH,
Barry JA,
and
Ramaswamy K.
Transport of propionate by human ileal brush-border membrane vesicles.
Am J Physiol Gastrointest Liver Physiol
260:
G776-G782,
1991[Abstract/Free Full Text].
18.
Harig, JM,
Soergel KH,
Komorowski RA,
and
Wood CM.
Treatment of diversion colitis with short-chain-fatty acid irrigation.
N Engl J Med
320:
23-28,
1989[Abstract].
19.
Hodin, RA,
Meng S,
Archer S,
and
Tang R.
Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells.
Cell Growth Differ
7:
647-653,
1996[Abstract].
20.
Mascolo, N,
Rajendran VM,
and
Binder HJ.
Mechanism of short-chain fatty acid uptake by apical membrane vesicles of rat distal colon.
Gastroenterology
101:
331-338,
1991[ISI][Medline].
21.
McIntyre, A,
Gibson PR,
and
Young GP.
Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.
Gut
34:
386-391,
1993[Abstract].
22.
McNeil, NI,
Cummings JH,
and
James WP.
Short chain fatty acid absorption by the human large intestine.
Gut
19:
819-822,
1978[Abstract].
23.
Meng, S,
Wu JT,
Archer SY,
and
Hodin RA.
Short-chain fatty acids and thyroid hormone interact in regulating enterocyte gene transcription.
Surgery
126:
293-298,
1999[ISI][Medline].
24.
Poole, RC,
and
Halestrap AP.
Transport of lactate and other monocarboxylates across mammalian plasma membranes.
Am J Physiol Cell Physiol
264:
C761-C782,
1993[Abstract/Free Full Text].
25.
Price, NT,
Jackson VN,
and
Halestrap AP.
Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past.
Biochem J
329:
321-328,
1998[ISI][Medline].
26.
Ritzhaupt, A,
Ellis A,
Hosie KB,
and
Shirazi-Beechey SP.
The characterization of butyrate transport across pig and human colonic luminal membrane.
J Physiol (Lond)
507:
819-830,
1998[Abstract/Free Full Text].
27.
Ritzhaupt, A,
Wood IS,
Ellis A,
Hosie KB,
and
Shirazi-Beechey SP.
Identification and characterization of a monocarboxylate transporter (MCT1) in pig and human colon: its potential to transport L-lactate as well as butyrate.
J Physiol (Lond)
513:
719-732,
1998[Abstract/Free Full Text].
28.
Roediger, WE.
Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.
Gut
21:
793-798,
1980[Abstract].
29.
Roediger, WE.
Utilization of nutrients by isolated epithelial cells of the rat colon.
Gastroenterology
83:
424-429,
1982[ISI][Medline].
30.
Ruppin, H,
Bar-Meir S,
Soergel KH,
Wood CM,
and
Schmitt MG, Jr.
Absorption of short-chain fatty acids by the colon.
Gastroenterology
78:
1500-1507,
1980[ISI][Medline].
31.
Scheppach, W,
Sommer H,
Kirchner T,
Paganelli GM,
Bartram P,
Christl S,
Richter F,
Dusel G,
and
Kasper H.
Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis.
Gastroenterology
103:
51-56,
1992[ISI][Medline].
32.
Siavoshian, S,
Blottiere HM,
Le Foll E,
Kaeffer B,
Cherbut C,
and
Galmiche JP.
Comparison of the effect of different short chain fatty acids on the growth and differentiation of human colonic carcinoma cell lines in vitro.
Cell Biol Int
21:
281-287,
1997[ISI][Medline].
33.
Stein, J,
Schroder O,
Milovic V,
and
Caspary WF.
Mercaptopropionate inhibits butyrate uptake in isolated apical membrane vesicles of the rat distal colon.
Gastroenterology
108:
673-679,
1995[ISI][Medline].
34.
Tiruppathi, C,
Balkovetz DF,
Ganapathy V,
Miyamoto Y,
and
Leibach FH.
A proton gradient, not a sodium gradient, is the driving force for active transport of lactate in rabbit intestinal brush-border membrane vesicles.
Biochem J
256:
219-223,
1988[ISI][Medline].
35.
Treem, WR,
Ahsan N,
Shoup M,
and
Hyams JS.
Fecal short-chain fatty acids in children with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr
18:
159-164,
1994[ISI][Medline].
36.
Von Engelhardt, W,
Burmester M,
Hansen K,
Becker G,
and
Rechkemmer G.
Effects of amiloride and ouabain on short-chain fatty acid transport in guinea-pig large intestine.
J Physiol (Lond)
460:
455-466,
1993[Abstract].
37.
Von Engelhardt, W,
Gros G,
Burmester M,
Hansen K,
Becker G,
and
Rechkemmer G.
Functional role of bicarbonate in propionate transport across guinea-pig isolated caecum and proximal colon.
J Physiol (Lond)
477:
365-371,
1994[Abstract].
38.
Whitehead, RH,
Young GP,
and
Bhathal PS.
Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215).
Gut
27:
1457-1463,
1986[Abstract].
39.
Yabuuchi, H,
Tamai I,
Sai Y,
and
Tsuji A.
Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter.
Pharm Res
15:
411-416,
1998[ISI][Medline].
Am J Physiol Gastrointest Liver Physiol 279(4):G775-G780